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Abstract
Introduction: Increasing evidence suggests a role for the gut microbiome in central nervous 
system disorders and specific role for the gut-brain axis in neurodegeneration. Bile acids (BA), 
products of cholesterol metabolism and clearance, are produced in the liver and are further 
metabolized by gut bacteria. They have major regulatory and signaling functions and seem 
dysregulated in Alzheimer disease (AD).
Methods: Serum levels of 15 primary and secondary BAs and their conjugated forms were 
measured in 1,464 subjects including 370 cognitively normal older adults (CN), 284 with early 
mild cognitive impairment (MCI), 505 with late MCI, and 305 AD cases enrolled in the AD 
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Neuroimaging Initiative. We assessed associations of BA profiles including selected ratios with 
diagnosis, cognition, and AD-related genetic variants, adjusting for cofounders and multiple 
testing.
Results: In AD compared to CN, we observed significantly lower serum concentrations of a 
primary BA (cholic acid CA) and increased levels of the bacterially produced, secondary BA, 
deoxycholic acid (DCA), and its glycine and taurine conjugated forms. An increased ratio of 
DCA:CA, which reflects 7α-dehydroxylation of CA by gut bacteria, strongly associated with 
cognitive decline, a finding replicated in serum and brain samples in the Rush Religious Orders 
and Memory and Aging Project. Several genetic variants in immune response related genes 
implicated in AD showed associations with BA profiles.
Conclusion: We report for the first time an association between altered BA profile, genetic 
variants implicated in AD and cognitive changes in disease using a large multicenter study. These 
findings warrant further investigation of gut dysbiosis and possible role of gut liver brain axis in 
the pathogenesis of AD.
Keywords
Metabolomics; metabolome; lipidomics; Alzheimer’s disease; gut microbiome; gut liver brain 
axis; atlas for Alzheimer; genetic variants; immunity; inflammation
1. Introduction
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the leading cause of 
dementia in old age affecting over 40 million people worldwide[1]. There are currently no 
therapies to prevent or slow AD progression, highlighting our incomplete knowledge of 
disease mechanisms and the need for new drug targets. A large number of biochemical 
processes are affected in AD and genes implicated in AD highlight the possible roles for 
lipid processing, immune function, phagocytosis, (innate) immunity and neurotransmitter 
function, biological pathways that may affect metabolism[2, 3]. Recent AD hypotheses 
implicate viral and bacterial contributions to disease pathogenesis[4-6].
Bidirectional biochemical communication between the brain and the gut contribute to a 
variety of neurodegenerative and psychiatric diseases[7-10]. The gut microbiome and the 
host collaboratively produce a large array of small molecules that impacts human health[11, 
12]. Recently, a role for the gut microbiome in motor dysfunction in Parkinson’s disease has 
been highlighted[13] and several animal models of AD showed a possible role of gut 
bacteria in amyloid-beta (Aβ) pathology[14, 15]. The APP transgenic mouse model of AD 
had a drastically altered gut microbiome composition compared to wild-type mice[15]. 
Other studies linked pro-inflammatory bacteria, such as gram-negative producers of 
neurotoxic lipopolysaccharides, to brain amyloidosis and systemic inflammation, a central 
feature of AD[16, 17]. These studies suggest microbial dysbiosis or imbalance could 
potentially contribute to AD pathogenesis.
Cholesterol metabolism in the liver is thought to play a key role in AD[18]. In fact, many 
cholesterol metabolism related genes (e.g., BIN1, CLU, PICALM, ABCA7, ABCG1, and 
SORL1) are among the top AD susceptibility loci identified by genome-wide association 
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studies[2, 19]. Cholesterol is cleared through production of bile acids (BAs). Primary BAs, 
chenodeoxycholic acid (CDCA) and cholic acid (CA), are synthesized from cholesterol in 
the liver, conjugated with glycine or taurine, secreted into the gallbladder via the bile salt 
export pump (BSEP), and transported to the intestine to be metabolized by gut bacteria (Fig. 
1). Intestinal anaerobic bacteria deconjugate the liver-derived BAs through the action of bile 
salt hydrolases (BSH) to their respective free BAs. Subsequently, anaerobe bacteria convert 
primary BAs to the secondary BAs. That is, CA is converted to deoxycholic acid (DCA). 
CDCA is converted to lithocholic acid (LCA) and ursodeoxycholic (UDCA) through 7α or 
7β –dehydroxylation, respectively[20, 21]. In the terminal ileum and colon, BAs are 
reabsorbed by the enterocytes and released into the portal vein for return to the liver where 
they are conjugated to produce their glycine and taurine forms.
Beyond BAs role in cholesterol clearance, BAs are major regulators for maintaining energy 
homeostasis through binding to nuclear receptors, including FXR and LXR among others. 
BAs also modulate the gut microbiome[22, 23] and seem to be indicators of gut dysbiosis. 
Both primary and secondary BAs are present in the brains of mice and possibly humans with 
evidence that they cross the blood-brain barrier[24-29]. Some BAs such UDCA exert 
beneficial effects while others are known to be cytotoxic[30-34]. In particular, DCA’s 
toxicity has been associated with modulating apoptosis involving mitochondrial pathways in 
a variety of tissues and cell types[35-38].
In recent pilot human studies, BA profiles were shown to be affected in AD[26, 39-42]. 
Here, we used a targeted metabolomics approach to evaluate BA profiles in a large cohort of 
1,464 individuals enrolled in the AD Neuroimaging Initiative (ADNI) where rich clinical, 
imaging, and genetic data exist. A schematic representation of study design is shown in Fig. 
2. We used this data to address the following:
1. Investigate if BA profiles are altered in MCI and AD patients and if these 
differences are related to cognitive decline.
2. Use ratios of BAs to pinpoint possible enzymatic alterations in the liver and in 
the gut microbiome that directly contribute to altered BA profile.
3. Investigate whether immune related AD genome-wide significant genes affect 
levels of BAs in circulation as markers for altered gut microbiome function.
In a subsequent paper we evaluated correlations between BAs and ATN (amyloid, tau, and 
neurodegenerative) biomarkers of AD including cerebrospinal fluid (CSF) biomarkers, brain 
atrophy, and brain glucose metabolism.
2. Methods
2.1. Study cohorts and samples:
2.1.1. ADNI baseline samples—Data used in the preparation of this article were 
downloaded from the ADNI database (http://adni.loni.usc.edu/). The ADNI studies have 
recruited over 1,500 adults, ages 55 to 90, consisting of cognitively normal older individuals 
(CN), individuals with subjective memory concerns (SMC), subjects with early (EMCI) or 
late mild cognitive impairment (LMCI), and patients with early probable AD dementia. 
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Subjects categorized as SMC were excluded in this study. For key clinical and demographic 
variables of ADNI participants included in this study, see Table 1.
2.1.2. The Religious Orders Study and the Rush Memory and Aging Project 
(ROS/MAP) for replication of key finding—The ROS/MAP studies are both 
longitudinal cohort studies of aging and AD at Rush University, and are designed to be used 
in joint analyses to maximize sample size. ROS enrolled individuals from religious orders 
(nuns, priests, brothers) across the United States[43]. MAP was designed to complement the 
ROS study by using a similar structure and design as ROS, but enrolling participants with a 
wider range of life experiences and socioeconomic status from the Chicago, IL metropolitan 
area[44]. The entire ROS/MAP cohort consists of approximately 3,300 participants, more 
than 1,500 of whom have come to autopsy (www.radc.rush.edu). We measured a subset of 
serum BAs in 566 subjects (446 CN, 109 MCI, and 11 AD), as well as a subset of BAs in 
postmortem brain samples from the dorsolateral pre-frontal cortex of 111 subjects with brain 
pathology measured (51 CN, 31 MCI, and 27 AD at time of death), of whom 93 had serum 
BA measurements. Key demographic characteristics of the ROS/MAP cohort are in 
Supplementary Table 1.
2.1.3. Rotterdam study (RS)—RS was used to examine the association of BAs with 
AD genetic variants. RS is a prospective population based study[45]. At the baseline 
examination in 1990-93, 7983 subjects ≥ 55 years of age were recruited from the Ommoord 
district of Rotterdam (RS-I). All the study participants were extensively interviewed and 
physically examined at baseline and after every 3 to 4 years. During 2000 to 2001, the 
baseline cohort (RS-I) was expanded with 3011 subjects ≥55 years of age, who were not yet 
part of RS-I (RS-II). In this analysis, fasting serum BAs were measured for 488 dementia-
free subjects with mean(SD) age of 73.1(6.3) from RS-I using Metabolon platform (Durham, 
North Carolina, USA) as described previously[46] (see Supplementary Table 2 for 
demographics).
2.2. Sample collection and quantification of BAs
Targeted metabolomics profiling was performed to measure concentrations of 20 BA 
metabolites in serum samples of the ADNI cohorts. Morning fasting serum samples from the 
baseline visit were collected and aliquoted as described in the ADNI standard operating 
procedures. BA quantification was performed by liquid chromatography tandem mass 
spectrometry using the Biocrates® Life Sciences Bile Acids Kit (BIOCRATES Life Science 
AG, Innsbruck, Austria) according to manufacturer’s instructions (see Table 2 for list of 
BAs, abbreviations and their levels across diagnosis groups).
In the ROS/MAP, quantification of BA concentrations in 566 serum samples and 111 
postmortem brain samples was performed at the University of Hawaii cancer center using 
ultraperformance liquid chromatography coupled to a tandem mass spectrometry (UPLC-
MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA)[47].
In the RS study, serum BAs were measured in 488 serum samples using the non-targeted 
Metabolon platform (Durham, North Carolina, USA).
MahmoudianDehkordi et al. Page 5













2.3. Quality control of BA profiles
Metabolomics lab staff were blinded to diagnosis and pathological data in all the studies. In 
ADNI, after unblinding and data release, metabolite profiles went through quality-control 
(QC) checks and data preprocessing including batch-effect adjustment, missing value 
imputation, and log-transformation (Supplementary Methods and Supplementary Table 3). 
After QC correction, the dataset included 15 BAs (5 BAs did not pass QC criteria) for a total 
of 1,464 subjects (after excluding 99 SMC). The preprocessed BA values after QC were 
used for subsequent association analyses directly or were adjusted to take into account the 
effect of medications on BA levels[48]. The list of medications selected for adjustment for 
each BA is shown in Supplementary Table 7. We performed all analyses using both 
medication adjusted and unadjusted BA levels, results derived from medication-adjusted 
data and the adjustment process are described in Supplementary Methods and its 
accompanying tables.
In both RS and ROS/MAP, missing metabolite levels were imputed using half of the limit of 
detection. Log-transformed values were used in subsequent analyses.
2.4. Clinical Outcomes
For ADNI data, continuous response variables included the modified Alzheimer Disease 
Assessment Scale 13-item cognitive subscale (ADAS-Cog13; range, 0 [best] to 85 [worst] 
points), an index of general cognitive functioning. Categorical response variables included 
clinical diagnosis at baseline and MCI conversion (MCI-NonConverter, MCI-Converter). For 
the ROS/MAP cohort, cognition was measured using a battery of tests (details are 
published[49-52]). A composite measure of global cognition was created by averaging the z-
scores of all tests as previously described[52]. Mean and standard deviation at baseline were 
used to compute z-scores. A negative z-score means that an individual has an overall score 
that is lower than the average of the entire sample at baseline. Cognitive tests were used 
from the same cycle as serum, and proximate to death for brain.
2.5. Genotype and whole genome sequencing data
Whole genome sequencing: For 817 ADNI participants, whole-genome sequencing 
(WGS) was performed on blood-derived genomic DNA. Samples were sequenced on the 
Illumina HiSeq2000 using paired-end read chemistry and read-length of 100bp at 30–40X 
coverage. For data processing and QC, an established analysis pipeline based on GATK was 
used. The QC steps included participant sex check, participant identity check, and variant 
quality check of the Illumina-generated VCF files (see Saykin et al., 2015 for details[53]).
DNA genotyping in the participants of the RS cohort was performed using 550K, 550K duo, 
or 610K Illumina arrays at the internal genotyping facility of the Erasmus Medical Center, 
Rotterdam. Study samples with excess autosomal heterozygosity, call rate < 97.5%, ethnic 
outliers, and duplicate or family relationships were excluded during quality control analysis. 
Genotype exclusion criteria further included call rate < 95%, Hardy-Weinberg equilibrium p 
< 1.0×10−6 and Minor Allele Frequency (MAF) < 1%. Genetic variants were imputed to the 
Haplotype Reference Consortium (HRC) reference panel (version 1.0)[54] using the 
Michigan imputation server[55].
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Reference genetic associations with BA profiles in healthy individuals were obtained from 
supplementary data of the atlas of genetic influences on blood metabolites[46]. To obtain 
genome-wide genetic associations with DCA, we considered all suggestive significant 
results with P < 1.0 × 10−5. Gene and complex trait annotations of the 13 resulting genetic 
loci were performed using the SNiPA tool v3.2[56] and the NHGRI-EBI Catalog of 
published genome-wide association studies (www.ebi.ac.uk/gwas; accessed 02/01/2018, 
version 1.0)[57]. Lookup of AD genetic associations for DCA candidate variants was 
performed using the IGAP repository[2].
2.6. Statistical analysis
Differences of demographic, clinical, and cognitive measurements among the clinical 
diagnostic groups were evaluated using 2-sample t-test (for continuous variables) and 
Pearson Chi-squared test (for categorical variables). All analyses were performed in a 
metabolite-wise manner and Bonferroni-adjusted critical values were used to assess 
statistical significance. All models included age at baseline, sex, APOE ε4, and log10-
transformed body mass index (BMI). For cognition, number of years of education was added 
as an additional covariate.
Separate binary logistic regression models were conducted to examine cross-sectional 
association of each metabolite with baseline diagnosis (6 models per metabolite). We 
performed logistic regression models to compare BA levels between the MCI-NonConverter 
and MCI-Converter groups. Cox proportional hazard models were used to evaluate the 
association of metabolite levels with progression from MCI (combined EMCI and LMCI 
subjects) to AD. The cross-sectional association of ADAS-Cog13 with BAs was assessed 
using linear regression models with square root of ADAS-Cog13 as the dependent variable.
In ROS/MAP, one sample per individual was used. Linear regression models with global 
cognition score as dependent variable and metabolites as independent variables were used to 
assess the association of serum BAs with cognition, while adjusting for sex, age, APOE ε4, 
and years of education. Similar analyses were conducted for brain BAs separately.
We restricted our genetic variant analysis to single nucleotide polymorphisms (SNPs) in 
genes involved in the immune response pathway that were significantly associated with AD 
genome-wide[2, 58-60]. Selected genetic variant included rs616338-T(ABI3), rs143332484-
T(TREM2), rs72824905-C(PLCG2), rs9331896-T(CLU), rs6656401-A(CR1), rs35349669-
T(INPP5D), rs11771145-G(EPHA1), rs983392-A(MS4A6A), and rs190982 -A(MEF2C). 
Associations of AD risk variants in immune-related genes with selected metabolic traits in 
ADNI and RS were computed using sex, age, and BMI as covariates.
3. Results
Characteristics of ADNI participants are depicted in Table 1. Baseline cognitive 
measurements were significantly different among diagnostic groups, as expected. AD 
patients were more often carriers of at least one APOE ε4 allele. In addition, ADAS-Cog13 
scores were not significantly different between the MCI-converter and Non-Converter 
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groups. However, the proportion of APOE ε4 carriers was higher in the MCI-Converter 
group.
3.1. Serum BA profiles are significantly altered in AD
The Bonferroni-corrected threshold for statistical significance was determined as P < 4.76 × 
10−4 (0.05 divided by 15 metabolites times 7 phenotypes including cognition). When we 
compared BA profile in AD to CN, we detected a significant decrease in levels of the 
primary BA, CA (P = 1.56 × 10−4). In contrast, a significant increase of bacterially produced 
secondary BA, DCA was noted (P = 1.61 × 10−4) along with several secondary conjugated 
BAs, GDCA, TDCA, and GLCA (Table 3). GDCA and GLCA were significantly associated 
with ADAS-Cog13 where higher levels indicate worse cognition. Comparing BA levels 
between AD and both MCI groups yielded similar results, while the comparison of BA 
levels between the CN and MCI groups did not reach statistical significance (Supplementary 
Table 4).
3.2. Ratios reflective of conversion of BAs by gut microbiome are significantly associated 
with AD and cognitive performance
To determine which enzymatic processes in BA metabolism may underlie the differences 
noted in AD, we investigated eight selected ratios reflective of enzymatic activities in the 
liver and the gut microbiome. These ratios included:
1. The CA:CDCA ratio was selected to test if a possible shift in BA synthesis from 
the primary to the alternative BA pathway occurs in the liver.
2. Ratios of secondary to primary BAs (DCA:CA, GLCA:CDCA, and 
TLCA:CDCA) to investigate differences in gut microbiome enzymatic activity 
leading to altered production of secondary BAs. Since LCA was excluded in QC 
steps, the GLCA:CDCA and TLCA:CDCA ratios were used as proxies for 
LCA:CDCA ratio.
3. GDCA:DCA and TDCA:DCA ratios were used to test if the observed secondary 
BA dysregulation is related to enzymatic differences related to their taurine and 
glycine conjugation.
Here, we considered associations as significant at a Bonferroni-corrected P < 3.11 × 10−4 
(0.05 divided by all 23 metabolic traits times 7 phenotypes, which include cognition). The 
ratio of the primary BAs (CA:CDCA) showed no significant association with AD. Yet, for 
the ratio of DCA:CA (i.e. the conversion of unconjugated primary to unconjugated 
secondary BA) we observed a highly significant association with AD diagnosis (P=1.53 × 
10−8). Ratios between primary and secondary conjugated BAs showed the same effect and 
direction, including GDCA:CA (P=8.53 × 10−10), TDCA:CA (P=9.83 × 10−7), and 
GLCA:CDCA (P=3.61 × 10−6). Ratios modeling the glycine and taurine conjugation step of 
DCA (i.e. GDCA:DCA, TDCA:DCA) were not significantly associated with diagnosis (Fig. 
3 and Table 4).
Four ratios (including DCA:CA and GLCA:CDCA) were significantly associated with 
ADAS-Cog13. For the ratios we observed the same pattern as AD diagnosis, with higher 
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ratios of secondary to primary BAs being highly significantly associated with worse 
cognitive performance, while neither conjugation, nor a shift between primary and 
alternative BA pathways in the liver were significantly linked to cognition (Table 4).
3.3. Serum BA levels were associated with progression from MCI to AD in ADNI
The 9 metabolites and ratios associated with diagnosis were further investigated to assess 
their relationship with progression from MCI to AD. Out of 789 MCI (EMCI and LMCI) 
patients with mean (SD) follow-up 3.94 (2.35), 32.2% progressed to AD dementia in four 
years (labeled as MCI-Converter (n=251) vs. those that did not progressed MCI Non-
Converter (n=538)). BA profiles were compared between the two groups using logistic 
regression models with conversion status as dependent variable and metabolite as 
independent variable. Models were adjusted for age, sex, BMI, baseline ADAS-Cog13 score, 
and APOE ε4. The Bonferroni-corrected threshold for statistical significance was 
determined as P < 5.56 × 10−3 (0.05 divided by 9 metabolites and ratios). We noted a 
decrease in CA levels (P=9.12 × 10−4) and an increase in ratios of GDCA:CA (P=1.63 × 
10−3) and TDCA:CA (P=1.72 × 10−3) in MCI-Converters (Fig. 4 and Supplementary Table 
5). Further survival analysis also revealed that levels of CA (hazard ratio (HR), 0.92; P =3.79 
× −3), GDCA:CA (HR, 1.07; P=2.81 × −3), and TDCA:CA (HR, 1.06; P=3.19 × 10−3) ratios 
predicted MCI progression (Fig. 4).
3.4. Replication of association between cognition and DCA:CA ratio in serum and brain 
from ROS/MAP
In order to confirm the associations observed in ADNI, we used an independent cohort of 
older adults (ROS/MAP) with measures of BAs in serum and brain to replicate our findings. 
Since the sample sizes in ROS/MAP were smaller than ADNI and AD cases were strongly 
underrepresented (566 serum samples 11 of which were AD and 111 brains 27 of which 
were AD), we focused on replicating our key findings related to the association between 
cognition and the DCA:CA ratio (as proxy for BA processing by the gut microbiome). Here 
we had to use global cognition scores where higher values indicate better cognition. Separate 
linear regression models were used for brain and serum samples. Pearson’s correlation 
coefficient between serum DCA:CA and DCA:CA in 93 matching brain samples was 0.303 
(P=0.003). In both serum and brain samples, higher levels of DCA:CA were associated with 
worse cognition (serum: β = −0.06; P = 0.011; brain: β = −0.21; P = 0.032), confirming our 
ADNI finding.
3.5. Genetic risk variants for AD in genes related to immune function are associated with 
bile acid levels
To further evaluate that altered BA profiles in AD are related to processes in the gut 
microbiome, we investigated if BA profiles were associated with immune-related AD risk 
genes which may contribute to differences in gut microbiome composition. Using the ADNI 
(n=817 with WGS data) and RS (n=488) cohorts, association of selected BAs in the primary 
BA pathway (CA, DCA, GDCA, and TDCA) as well as the DCA:CA ratio with the selected 
genetic risk variants in 9 candidate genes with immune-related functions was assessed. In 
addition, we included associations from a published large cohort-based study [46] to 
increase sample size. With the exception of rs983392 inMS4A6A, we found nominally 
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significant associations for the candidate variants in all of these genes (Supplementary Table 
10). Three associations were significant after Bonferroni-correction (P < 1.1 × 10−3) in at 
least one of the studies: rs616338 (ABI3) and rs190982 (MEF2C) were significantly 
associated with the DCA:CA ratio and rs11771145 (EPHA1) was significantly linked to 
both DCA and TDCA.
3.6. Genetic loci associated with DCA may influence susceptibility for AD
To follow up on the hypothesis that elevated DCA levels in AD which are linked to gut 
dysbiosis are relevant in the pathogenesis of AD, we collected (suggestive) significant 
genetic associations with DCA levels (P < 1.0 × 10−5) from a previous study of genetic 
influences on blood metabolite levels in large population-based cohorts (n~7,800)[46]. We 
then annotated the resulting 13 loci with genetic trait associations, including AD 
associations from the IGAP study[2], and tried to replicate associations with DCA in ADNI 
(Supplementary Table 11). Two of the 13 genes, CYP7A1 and IMPA2, also showed 
association with DCA levels in ADNI subjects. Notably, six of the 13 genes have been 
previously linked via genetic studies to AD (ABCA7) or AD phenotypes, including 
cognitive decline and CSF protein levels (LRRC7, CYCS, GPC6, FOXN3 and CNTNAP4).
4. Discussion
In this study, we interrogated a possible role for BA end products of cholesterol metabolism 
and clearance in cognitive changes in AD. Using stored blood samples from ADNI studies 
we established that BA profile is significantly altered in AD patients. We noted a significant 
decrease in serum levels of a liver-derived primary BA (CA) and an increase in levels of a 
bacterially produced secondary BAs and their conjugated forms (DCA, GDCA and TDCA, 
GLCA) in AD patients compared to CN subjects (Table 3, Fig. 1A). Higher levels of 
secondary conjugated BAs (GDCA, GLCA, and TLCA) were significantly associated with 
worse cognitive function (ADAS-Cog13; Table 3). In a follow up paper, we illustrate that 
these changes are also correlated with changes in CSF markers of disease and with brain 
imaging changes.
To inform about enzymatic activity changes in the liver and the gut, three types of metabolite 
ratios were evaluated to inform about mechanisms leading to the noted altered BA profile in 
AD. We found no shift in metabolism between primary and alternative pathways (Fig. 3; no 
change in CA:CDCA); a significant change in production of secondary BAs via enzymatic 
activities in the gut microbiome (increased DCA:CA as well as GLCA:CDCA and 
TLCA:CDCA as proxies for LCA:CDCA) and no change in processes involved in glycine 
and taurine conjugation of secondary BAs in the liver (no change in GDCA:DCA or 
TDCA:DCA). The significant increase in ratios of secondary to primary BAs (e.g. DCA:CA; 
Fig. 3), suggest altered activity of bacterial 7β-dehydroxylases leading to excess production 
of secondary BAs many of which are cytotoxic[34, 61-63]. This indicates potential gut 
dysbiosis in AD patients possibly caused by enhanced colonization of the large and possibly 
the small intestine with anaerobic bacteria capable of CA and CDCA 7α-dehydroxylation. 
Increases in these ratios also significantly correlated with poorer cognition (Table 4). 
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Together, these findings suggest that enzymatic steps in conversion of primary to secondary 
BAs in the gut might contribute to disease.
We also evaluated effects of BA levels on risk of progression to AD among 789 MCI 
patients. Lower levels of CA and higher ratio of secondary to primary BAs, GDCA:CA, and 
TDCA:CA were significantly associated with risk of developing AD dementia (Fig. 4, 
Supplementary Table 6).
The increased production of bacterially produced DCA from CA modeled by ratio DCA:CA 
and its link to cognition was replicated in the independent ROS/MAP cohort. Association of 
the DCA:CA ratio with disease severity was evaluated separately in 566 serum and 111 
brain samples. Due to the small number of AD patients (n=11, serum n=27, brains), we used 
global cognitive scores as an index of disease severity. Most of the BAs primary and 
bacterially produced secondary were found in the brain. Similar to ADNI findings, an 
increase in the DCA:CA ratio in both serum and brain were significantly associated with 
worse cognition. This finding suggests that downstream effects of the gut-directed 
dysregulation of primary vs. secondary BAs are not limited to the periphery, but also might 
affect metabolic homeostasis and/or signaling functions in the human brain.
Earlier smaller studies suggested differences in BA levels in AD [26, 38-42]. For example, 
in a study of 495 plasma metabolites comparing MCI (n=58) and AD (n = 100) with those of 
cognitively normal controls (n=93), levels of DCA, LCA, and GLCA were significantly 
elevated in the disease state [41]. Mapstone and colleagues[39] identified increased levels of 
glycoursodeoxycholic acid (GUDCA) in subjects likely to develop amnestic MCI or AD 
within 2 to 3 years compared to controls. In a small pilot study Marksteiner and colleagues 
[42] reported increased levels of LCA, GDCA, and GLCA in AD (n=30) relative to MCI 
(n=20). We replicated these findings with the exception of LCA (excluded during QC) and 
GUDCA which showed only a non-significant trend of upregulation in the AD group (P = 
0.054). Marksteiner [42] did not report a significant increase in DCA or decrease in CA 
which we observed in the ADNI cohort. However, there is a trend in their data to suggest 
that DCA levels are increased in AD relative to CN. Our analyses build upon these pilot 
studies to include a large well-characterized cohort with rich clinical, neuroimaging, and 
genetics data. Our analyses include links to innate immunity related genes which was not 
possible in smaller studies. In addition, we controlled for medication use which is known to 
significantly affect the gut microbiome and bile acids. In our follow-up paper we explore the 
association of serum BAs with CSF and neuroimaging biomarkers of AD.
Composition and functional changes of the gut microbiome have been implicated in several 
diseases. Microbiome GWAS revealed that variants in many human genes involved in 
immunity and gut architecture are associated with an altered gut microbiome composition 
[64]. Although many factors such as diet can affect the microbial organisms residing in the 
gut, emerging data support the hypothesis that certain host genetic variants predispose an 
individual towards microbiome dysbiosis and this can be linked to disorders of metabolism 
and immunity such as type 2 diabetes mellitus, obesity, and autism[64].
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Accumulating evidence links dysregulation of the immune system to AD pathology. In 
particular, genetic association studies in AD have robustly identified several genetic risk 
variants in immune-related genes[2, 60]. Using the ADNI and RS cohorts, we investigated 
the association of BA profiles of CN subjects with genetic variants in nine AD-related and 
innate immunity genes. Eight genetic variants were associated with selected BA levels at 
nominal significance (Supplementary Table 10). Three of these associations were significant 
after Bonferroni-correction, with rs616338 (ABI3) and rs190982 (MEF2C) associated with 
the DCA:CA ratio, and rs11771145 (EPHA1) linked to both DCA and TDCA. The 
association of the BAs to AD genes suggest that these immune related genes may influence 
the risk of AD through BA metabolism or changes in the gut microbiome. Interestingly, both 
ABI3 and MEF2C are thought to be involved in immune reactions to pro-inflammatory 
stimuli that are partially secreted by microbes[65, 66]. The link to the DCA:CA ratio may 
thus mirror differences in gut microbiome composition due to altered immune response in 
AD, providing a mechanistic hypothesis for our findings. The function of EPHA1 is not well 
understood but it has been hypothesized that when activated, this receptor may affect the 
integrity of the blood brain barrier (BBB)[67]. Its association with levels of DCA is 
intriguing as DCA is known to be cytotoxic and can disrupt the BBB and then enter the 
brain[28]. rs11771145 is associated with gene expression levels of EPHA1[56], and as DCA 
is not known to be produced by human metabolism, changed expression and activity of 
EPHA1 may be related to DCA-mediated cytotoxic effects.
Using an established atlas of genetic influences on human blood metabolites[46], we further 
investigated a potential cytotoxic role of DCA. For almost half of the 13 identified loci, we 
found genetic evidence for involvement in AD-linked complex traits (Supplementary Table 
11). In particular, ABCA7 is an AD risk gene replicated in several genetic studies[68, 69]. 
Five additional genes (LRRC7, CYCS, GPC6, FOXN3, and CNTNAP4) genetically 
influence AD phenotypes, including cognitive decline and CSF markers. While it remains 
speculative if and how these genes interact with DCA to contribute to AD risk, it is 
intriguing that we identified ABCA7 by screening for associations with DCA levels. 
ABCA7 is highly expressed in the brain, and functions in the efflux of lipids, including 
cholesterol, from cells. Due to the structural similarity of DCA and cholesterol, we 
hypothesize that ABCA7 may be able to also transport this BA, reconciling metabolomics 
findings via a functional hypothesis to a risk gene for AD. The findings that BA levels are 
regulated by AD related genes might provide new mechanistic insights.
There is growing support for strong connections between the intestinal environment, with its 
diverse microbial composition and activity, and the functions of the central nervous system. 
The “gut-brain metabolic axis” facilitates bidirectional chemical communication between 
the central and enteric nervous systems through mechanisms just starting to be defined[7-9]. 
Such a metabolic axis is thought to be involved in the regulation of multiple host metabolic 
pathways in which levels of hormones, neurotransmitters, amines, GABA, short-chain fatty 
acids (SCFA), lipid metabolites, and others are regulated by gut microbiome activity[12]. 
Changes in the composition of intestinal bacterial populations are associated with a wide 
array of neurological and neurodevelopmental disorders including multiple sclerosis, autism, 
depression, schizophrenia, and Parkinson’s disease[70-72]. In addition, increasing evidence 
suggest that liver disease may impact cognitive functions and contribute to AD[73].
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Our findings suggest novel metabolic links in AD where BAs represent a component of the 
gut-liver-brain axis that relates to cognition. We hypothesize that interconnected immune 
and gut microbiome dysregulation leads to increase in production of cytotoxic secondary 
bile acids like DCA and its derivatives and these can module the BBB and build up in the 
brain leading to impaired metabolic functions mediated by their receptors and targets. Such 
dysregulation includes cholesterol and glucose homeostasis.
It is of interest that BAs are ligands for nuclear receptors including FXR, LXRs among 
others and they acts synergistically as metabolic sensors to regulate energy homeostasis[74, 
75] peripherally and might also propagate their effects to the brain. Interestingly, levels of 
four BAs produced by the gut microbiome and that we show to be significantly correlated 
with disease status and cognition (DCA, GLCA, TLCA, TDCA) are hydrophobic and 
cytotoxic[34, 35, 76, 77]. Cell lines, animal models, and human studies suggest that levels of 
such BAs, particularly DCA, lead to a disruption of mitochondrial membranes resulting in 
increased reactive oxygen species, markers of inflammation, and apoptosis as well as 
decreases in cell viability and DNA synthesis[34, 35, 78]. Studies in rodents with deuterium 
labelled DCA, demonstrated DCA crosses the BBB and increases its permeability[27, 29]. 
Increased amounts of secondary BAs in blood may enter the brain through induced 
permeability of the BBB, affecting brain physiology and metabolism[28]. Several studies in 
human and animal brains also revealed that the full panel of BAs are found in the 
brain[24-27], but it is unclear whether this is due to transport from the periphery, from local 
synthesis, or both. The function of these BAs in the brain remains poorly defined with some 
support for them acting as neurosteroids[79].
BA levels and the gut microbiome influence each other, where BSH-rich bacteria readily 
modify the BA profile while, on the other hand, intestinal BAs control the growth and 
maintenance of commensal bacteria, maintain barrier integrity, and modulate the immune 
system[80-83]. Such changes might impact brain functions. Significant data support a role 
for cholesterol metabolism in the pathogenies of AD including large genetic studies. 
Cholesterol homeostasis is regulated in part by the gut microbiome suggesting that 
cholesterol intermediates including those produced by gut might present as one gut brain 
axis of communication that needs to be further investigated in human and animal studies.
4.1. Limitations
This is an observational study, the results of which may contain confounding biases. For 
example, diet, lifestyle, exposome and other factors may contribute to changes in the gut. It 
remains unclear how these important factors are related to AD pathogenesis and whether the 
observed differences we note are causes or consequences of disease. Further studies of 
metabolic changes in normal aging are required to help define which aspects of BA 
metabolism might be related to disease vs normal aging. Fecal material was not collected in 
the ADNI cohorts and most large studied therefore precluding a direct analysis of microbiota 
changes across the trajectory of disease. Such studies have just been initiated. Use of 
medications was extensively evaluated as a possible confound (Supplementary methods and 
Tables 7-9) and our key findings remained after controlling for medication use but larger 
studies need to further evaluate the effect of these medications. Additional experimental 
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studies are needed to more fully define the expression of BAs and their receptors in the brain 
and mechanistic roles of BAs in the development of AD. The impact of BAs on FXR, TGR5, 
vitamin, and hormone receptors in the brain and the signaling pathways impacted are 
currently unclear. It is important to evaluate in other large community studies the 
generalizability of our findings. The genetic links need to be tested in large populations.
Longitudinal studies covering pre-symptomatic stages are needed to establish the influence 
of immune changes on gut microbiome composition and activity in AD patients and the 
impact of this on BAs and cholesterol homeostasis. Tracking earliest changes in BA and 
other gut derived metabolites might provide insights into causality. Labeling studies are 
needed to evaluate if BAs cross the BBB and build up in brain with further elucidation of 
their signaling and regulatory functions centrally. However, we cannot exclude the 
possibility that changes in the brain during disease can also impact the gut and liver, and 
hence some of our findings might be brain derived.
5. Conclusions
In summary, there is evidence of a relationship among intestinal BA profile, gut microbial 
composition and/or activity, innate immunity, and genetic variants implicated in AD. When 
disrupted, BAs may contribute to cognitive changes, highlighting the importance of 
cholesterol clearance and its regulation in AD. Disorders in BA metabolism cause 
cholestatic liver diseases, dyslipidemia, fatty liver diseases, cardiovascular diseases, and 
diabetes, which are all associated with risk of cognitive decline, directly or indirectly. Our 
results lend support to this relationship in the context of AD and cohorts at risk for AD. Our 
evolving understanding of the gut microbiome’s role in aging and in central nervous system 
diseases and their progression could open potential new hypotheses in the field, regardless of 
whether the role is ultimately found to be causative, consequence, or contributory. The role 
of the gut microbiome in AD needs to be further investigated along with the emerging links 
between central and peripheral metabolic failures that might contribute to brain health and 
disease during aging.
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1. Systematic review: The authors reviewed the literature using PubMed, 
Google, Web of Science, Medline, Research Gate and through meeting 
abstracts and presentations. While the role of the gut microbiome in AD is not 
yet as widely studied, there are several recent publications implicating the 
gut's role in other neuropsychiatric diseases. These relevant citations are 
appropriately cited.
2. Interpretation: We report correlations between secondary gut microbiome 
produced BA and cognitive decline in AD with innate immunity genes 
contributing to altered BA profile. Our findings highlight a possible role for 
cholesterol clearance and gut microbiome in disease mechanism.
3. Future directions: Our evolving understanding of the gut microbiome's role 
in aging and related diseases could open new hypotheses for AD, regardless 
of whether the role is ultimately found to be causative, consequence, or 
contributory. These findings warrant further investigation of the possible role 
of gut liver brain axis in AD pathogenesis.
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Fig. 1. Bile acid synthesis and cholesterol clearance pathway.
Regulation of bile acid synthesis by feedback mechanism and bile acid transport through 
enterohepatic circulation. In the liver the bile acids (CDCA, DCA, LCA, CA) activate FXR 
that inhibits (via a repressor SHP, not shown here) the rate-limiting enzyme CYP7A1. The 
bile acids via FXR/SHP also inhibit the influx transporter NTCP; induce BSEP and 
canalicular bile acid secretion. In the intestine, bile acids, via FXR, inhibit the uptake 
transporter ASBT, decreasing absorption and increasing basolateral secretion into portal 
circulation by inducing OSTα & β. Bile acid activated FXR in the intestine also exerts 
inhibition on CYP7A1 in the liver via FGF19 pathway. At the basolateral membrane of 
hepatocytes, transporters OSTα & β, and also MRP3 and MRP4, secrete bile acids into the 
systemic circulation.
Abbreviations: ASBT: Apical Sodium-dependent Bile acid Transporters; BSEP: Bile Salt 
Export Pump; FXR: Farnesoid X Receptor; NTCP: Sodium/Taurocholate Co-transporting 
Polypeptide; SHP: Small heterodimer partner.
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Schematic representation of study design.
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Ratios of bile acids reflective of liver and gut microbiome enzymatic activities in CN, Early 
MCI, Late MCI and AD patients.
Three types of ratios were calculated to inform about possible enzymatic activity changes in 
Alzheimer’s patients. These ratios reflect one of the following: (1) Shift in bile acid 
metabolism from primary to alternative pathway. (2) Changes in gut microbiome correlated 
with production of secondary bile acids. (3) Changes in glycine and taurine conjugation of 
secondary bile acids. Color code: Green: cognitively normal; Yellow: EMCI; Blue: LMCI; 
Red: AD. Composition of selected ratios stratified by clinical diagnosis. Error bars indicate 
standard error of the means; Asterisks indicate statistical significance (*P<10−03, ** P< 
10−04, and ***P< 10−05). P-values were estimated from logistic regression models and 
adjusted for age, sex, body mass index, and APOE ε4 status. The significance level was 
adjusted for multiple testing according to Bonferroni method to 0.05/138 = 3.62E-4; LCA 
was excluded in the quality control steps.
MahmoudianDehkordi et al. Page 26














Comparison of bile levels in MCI subjects who convert and those who did not convert to AD 
dementia.
A and B. Lower levels of CA and higher levels of two secondary to primary ratios were 
significantly associated with higher odds of converting from MCI to AD. EMCI and LMCI 
patients that converted to AD dementia in 4 years after baseline were labeled as MCI-
Converter; 9 bile acids and ratios that were significantly dysregulated between CN to AD 
were assessed; P-values were estimated from logistic regression models and adjusted for 
age, sex, body mass index, and APOE ε4 status; the significance level was adjusted for 
multiple testing according to Bonferroni 0.05/9 = 5.56 × 10−3. C and D. Cox hazards model 
of the association of conversion from MCI to AD. Red line: 1st quantile, Red line: 3rd 
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quantile. Analysis was conducted using quantitative values and stratification by quantiles 
was used only for graphical representation.
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Table 1.A











Age 1464 74.58(5.71) 71.12(7.51) 73.95(7.59) 74.70(7.79) P<0.001
Sex: Female, No. (%) 1464 190(51%) 130(46%) 197(39%) 139(46%) P=0.004
Education, years 1464 16.28(2.92) 15.95(2.66) 15.87(2.90) 15.16(3.00) P<0.001
BMI (Kg/M2) 1461 27.05(4.46) 28.06(5.41) 26.54(4.25) 25.83(4.69) P<0.001
≥1APOE ε4 allele, No.(%) 1464 104(28%) 121(43%) 273(54%) 202(66%) P<0.001
ADAS-Cog13
c 1455 9.19(4.17) 12.64(5.40) 18.67(6.62) 29.67(8.20) P<0.001
a
Data are reported as mean(SD) unless otherwise indicated. Bolded values indicate statistical significance. SD: Standard deviation.
b
Based on 2-sample t tests, or Pearson χ2 tests.
c
Score explanations: ADAS-Cog13 range, 0 (best) to 85 (worst).
Abbreviations: AD: Alzheimer’s disease; BMI: Body mass index; CN: Cognitively normal; EMCI: Early mild cognitive impairment; LMCI: Late 
mild cognitive impairment; ADAS-Cog13, Alzheimer Disease Assessment Scale 13-item cognitive subscale.
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Table 1.B







Age 789 72.47(7.90) 73.91(7.08) P=0.01
Sex: Female, No. (%) 789 41% (223) 41% (104) P=1
Education, years 789 15.95(2.85) 15.79(2.76) P=0.43
BMI (Kg/M2) 788 27.37(4.80) 26.47(4.61) P=0.005
≥1APOE ε4 allele, No.(%) 789 41%(223) 68%(171) P<0.001
ADAS-Cog13 786 14.26(6.04) 21.31(5.94) P=0.29
a
MCI Subjects that converted to AD dementia in 4 years after baseline were labeled as MCI Converter.
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Table 2.













CA, Cholic Primary 1446 0.221(0.024) 0.155(0.021) 0.192(0.021) 0.135(0.025)
CDCA, Chenodeoxycholic Primary 1357 0.285(0.042) 0.241(0.034) 0.288(0.033) 0.216(0.033)
GCA, Glycocholic Primary Conjugated 1463 0.236(0.019) 0.234(0.021) 0.239(0.014) 0.297(0.037)
GCDCA, Glycochenodeoxycholic Primary Conjugated 1464 0.658(0.035) 0.724(0.059) 0.710(0.037) 0.806(0.049)
TCA, Taurocholic Primary Conjugated 1020 0.068(0.008) 0.057(0.006) 0.068(0.006) 0.066(0.009)
TCDCA, Taurochenodeoxycholic Primary Conjugated 1426 0.090(0.006) 0.088(0.007) 0.091(0.006) 0.097(0.008)
TMCA, Tauromuricholic Primary Conjugated 1146 0.012(0.001) 0.011(0.001) 0.014(0.002) 0.014(0.002)
DCA, Deoxycholic Secondary 1445 0.526(0.041) 0.574(0.043) 0.529(0.026) 0.627(0.045)
UDCA, Ursodeoxycholic Secondary 1111 0.065(0.007) 0.072(0.011) 0.091(0.010) 0.087(0.012)
GDCA, Glycodeoxycholic Secondary Conjugated 1439 0.440(0.034) 0.488(0.038) 0.502(0.031) 0.672(0.054)
TDCA, Taurodeoxycholic Secondary Conjugated 1430 0.058(0.006) 0.059(0.005) 0.065(0.005) 0.077(0.006)
GLCA, Glycolithocholic Secondary Conjugated 1037 0.027(0.002) 0.034(0.003) 0.030(0.002) 0.039(0.003)
TLCA, Taurolithocholic Secondary Conjugated 1008 0.005(0.0002) 0.005(0.0003) 0.005(0.0003) 0.006(0.0005)
GUDCA, Glycoursodeoxycholic Secondary Conjugated 1401 0.115(0.010) 0.114(0.012) 0.129(0.012) 0.136(0.015)
TUDCA, Tauroursodeoxycholic Secondary Conjugated 1369 0.008(0.001) 0.008(0.001) 0.008(0.001) 0.008(0.001)
a
Values represent μM in mean (standard error of the mean).
b
Number of non-missing measurements.
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Table 3.
Cross-sectional association of bile acids with clinical diagnosis and cognition in the ADNI study
a
.
Bile Acid CN vs. AD (n=673)
OR (95% CI); P-value
b
ADAS-Cog13 (n=1453)

















Statistically significant associations that passed Bonferroni correction are bolded.
b
Odds ratios and p-values were obtained from logistic regressions. Models were corrected for age, sex, body mass index, and APOE ε4 status; 
Bonferroni-adjusted critical value was set to 5.76 × 10−4 (0.05 divided by 15 metabolites times 7 phenotypes including cognition)
c
Outcome: Square root of ADASCog-13 (0 [best] to 85 [worst]); Models were corrected for age, sex, years of education, body mass index and 
APOE ε4 status; Bonferroni-adjusted critical value was set to 2.17E-03.













MahmoudianDehkordi et al. Page 33
Table 4.
Ratios of bile acids reflective of gut microbiome and liver enzymatic activities and their correlation with 










β(95% CI); P-value c
Bile acid synthesis: primary vs. alternative pathway CA:CDCA 0.87(0.77,0.97);1.67E-02 −0.03(−0.07,0.01);1.27E-01






TLCA:CDCA 1.09(1.03,1.16); 1.60E-03 0.03(0.01,0.05);1.50E-03





Several ratios were calculated to inform about possible enzymatic activity changes in Alzheimer’s patients. These ratios reflect: (1) Shift in bile 
acid metabolism from primary to alternative pathway. (2) Changes in gut microbiome correlated with production of secondary bile acids. (3) 
Changes in glycine and taurine conjugation of secondary bile acids.
b
Outcome: Baseline diagnosis; Odds ratios and p-values were obtained from logistics regressions. Models were corrected for age, sex, body mass 
index, and APOE ε4 status; Bonferroni-adjusted critical value was set to 1.04E-03 based on 6 possible pairwise comparison of diagnosis groups 
(CN, EMCI, LMCI, and AD) for 8 ratios.
c
Outcome: Square root of ADASCog-13 (0 [best] to 85 [worst]); Models were corrected for age, sex, years of education, body mass index, and 
APOE ε4 status; Bonferroni-adjusted critical value was set to .11 × 10−4 (0.05 divided by all 23 metabolic traits times 7 phenotypes, which include 
cognitive function).
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